Taysha Gene Therapies, Inc. (TSHA) DCF Valuation

Taysha Gene Therapies, Inc. (TSHA) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Taysha Gene Therapies, Inc. (TSHA) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Streamline your analysis and improve precision with our (TSHA) DCF Calculator! Utilizing real data from Taysha Gene Therapies, Inc. and customizable assumptions, this tool empowers you to forecast, analyze, and value (TSHA) like a seasoned investor.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 2.5 15.5 19.3 24.1 30.2 37.7 47.2
Revenue Growth, % 0 0 0 0 517.55 25 25 25 25 25
EBITDA .0 -43.0 -172.8 -159.7 -105.2 3.9 4.8 6.0 7.5 9.4
EBITDA, % 100 100 100 -6384.05 -680.84 20 20 20 20 20
Depreciation 4.5 .0 .5 2.5 1.4 15.8 19.7 24.6 30.8 38.5
Depreciation, % 100 100 100 99.4 8.87 81.65 81.65 81.65 81.65 81.65
EBIT -4.5 -43.0 -173.3 -162.2 -106.6 3.9 4.8 6.0 7.5 9.4
EBIT, % 100 100 100 -6483.45 -689.72 20 20 20 20 20
Total Cash .0 251.3 149.1 87.9 143.9 19.3 24.1 30.2 37.7 47.2
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 0 0
Inventories .0 .0 .0 .0 .0 11.6 14.5 18.1 22.6 28.3
Inventories, % 100 100 100 0 0 60 60 60 60 60
Accounts Payable .0 2.0 21.8 10.9 6.4 17.0 21.3 26.6 33.3 41.6
Accounts Payable, % 100 100 100 437.49 41.2 88.24 88.24 88.24 88.24 88.24
Capital Expenditure .0 -9.1 -21.6 -24.9 -7.4 -5.7 -7.1 -8.9 -11.1 -13.9
Capital Expenditure, % 100 100 100 -993.96 -47.69 -29.54 -29.54 -29.54 -29.54 -29.54
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -4.5 -30.8 -174.2 -165.7 -106.6 3.6 4.6 5.7 7.1 8.9
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF .0 -37.9 -175.5 -198.9 -117.1 1.2 15.6 19.5 24.4 30.5
WACC, % 6.81 6.28 6.81 6.81 6.81 6.71 6.71 6.71 6.71 6.71
PV UFCF
SUM PV UFCF 71.7
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 31
Terminal Value 660
Present Terminal Value 477
Enterprise Value 549
Net Debt -83
Equity Value 632
Diluted Shares Outstanding, MM 116
Equity Value Per Share 5.44

What You Will Get

  • Editable Excel Template: A fully customizable Excel-based DCF Calculator featuring pre-filled real TSHA financials.
  • Real-World Data: Historical data and forward-looking estimates (as indicated in the yellow cells).
  • Forecast Flexibility: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC.
  • Automatic Calculations: Instantly observe the impact of your inputs on Taysha Gene Therapies’ valuation.
  • Professional Tool: Designed for investors, CFOs, consultants, and financial analysts.
  • User-Friendly Design: Organized for clarity and ease of use, complete with step-by-step instructions.

Key Features

  • Comprehensive Data: Taysha Gene Therapies’ historical financial statements and pre-filled forecasts.
  • Customizable Inputs: Modify WACC, tax rates, revenue growth, and EBITDA margins as needed.
  • Real-Time Calculations: Observe Taysha Gene Therapies’ intrinsic value update instantly.
  • Intuitive Visualizations: Dashboard graphs present valuation results and essential metrics clearly.
  • Designed for Precision: A robust tool tailored for analysts, investors, and finance professionals.

How It Works

  • Download: Access the ready-to-use Excel file with Taysha Gene Therapies' (TSHA) financial data.
  • Customize: Adjust forecasts, including revenue growth, EBITDA %, and WACC.
  • Update Automatically: The intrinsic value and NPV calculations update in real-time.
  • Test Scenarios: Create multiple projections and compare outcomes instantly.
  • Make Decisions: Use the valuation results to guide your investment strategy.

Why Choose Taysha Gene Therapies, Inc. (TSHA)?

  • Innovative Solutions: Pioneering gene therapies that address unmet medical needs.
  • Expertise in Genetics: A team of leading scientists dedicated to advancing genetic medicine.
  • Patient-Centric Approach: Focused on developing treatments that enhance patient outcomes.
  • Robust Pipeline: A diverse range of therapies in various stages of development.
  • Commitment to Quality: Adherence to the highest standards in research and clinical trials.

Who Should Use Taysha Gene Therapies, Inc. (TSHA)?

  • Investors: Gain insights into gene therapy investments with our advanced research tools.
  • Researchers: Utilize comprehensive data to support innovative gene therapy projects.
  • Healthcare Professionals: Stay informed about the latest developments in gene therapies for patient care.
  • Biotech Enthusiasts: Explore the cutting-edge of genetic medicine and its potential impact.
  • Students and Educators: Leverage our resources for studies in biotechnology and gene therapy applications.

What the Template Contains

  • Pre-Filled Data: Includes Taysha Gene Therapies' historical financials and projections.
  • Discounted Cash Flow Model: Editable DCF valuation model with automated calculations.
  • Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on user-defined inputs.
  • Key Financial Ratios: Evaluate Taysha's profitability, efficiency, and leverage metrics.
  • Customizable Inputs: Easily modify revenue growth, margins, and tax rates.
  • Clear Dashboard: Visual representations and tables summarizing key valuation outcomes.

No products were found matching.